ClinicalTrials.gg
RecruitingNCT02099734Updated Nov 4, 2026

Germ Cell Tumor and Testicular Tumor DNA Registry

An observational study in Germ Cell Tumor and Testicular Tumor, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 8 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

From the registry’s dates

  • Started Jan 2014; still recruiting 12 years 10 months later.
Updated Nov 4, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 94 studies in Neoplasms, Germ Cell and Embryonal with a site in United States — 25 open to participants now, 36 under way, 3 of them phase 3. Neoplasms, Germ Cell and Embryonal · United States.

Planned enrollment
4th of 13
1,000 · median 213
Started
2014
with 5 others
Observational
13 of 94
4 open now
Primary completion
2028-01
later than 20 of 35 live
Registered
32nd of 94
by date
Lead sponsor
5 of 94
Memorial Sloan Kettering Cancer Center

Among the 94 studies in Neoplasms, Germ Cell and Embryonal with a site in United States, this one is the 4th largest by planned enrollment of the 13 observational ones that give a count, is one of 6 that started in 2014, is one of 13 observational ones, reaches primary completion later than 20 of the 35 other live ones, and was the 32nd registered.

Neoplasms, Germ Cell and Embryonal

167 studies on the registry are indexed under Neoplasms, Germ Cell and Embryonal; 49 are open to participants now.

Browse Neoplasms, Germ Cell and Embryonal studies →

Open to participants now

25 of the 94 studies in Neoplasms, Germ Cell and Embryonal with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Neoplasms, Germ Cell and Embryonal studies recruiting now, 20 (50%) set no upper age limit and 16 (40%) stop at 75 or younger; 22 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Neoplasms, Germ Cell and Embryonal with a site in United States, or all of them as a file.
02

Study summary

This study is being done to create a registry to help us learn more about germ cell tumors (GCT) and other testicular tumors. The registry will include people with these tumors and also relatives and unrelated people without these tumors. This study will help us learn more about the prevention, diagnosis, treatment and outcome of these tumors. Studying relatives of patients and people unrelated to patients with GCT and other testicular tumors will help us understand why some people get these tumors and why some people don't.

03

Conditions studied

  • Germ Cell Tumor
  • Testicular Tumor

Keywords

  • 14-016
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

At MSKCC, the following outpatient clinics will be used to recruit GCT and testicular tumor cases and controls: Urology (Department of Surgery), Gynecologic Oncology (Department of Surgery) Clinical Genetics, Genitourinary Oncology (Department of Medicine), and Gynecologic Medical Oncology (Department of Medicine).

Inclusion criteria

Case Cohort

  • Must be ≥ 18 years of age AND
  • Must be an English-speaker AND
  • Must have a diagnosis or suspicion of germ cell tumor and/or a testicular mass

Family Member Cohort

  • Must be ≥ 18 years of age AND
  • Must be an English-speaker AND
  • Must be a blood relative of the proband. Family members of probands are eligible. These individuals need not have a diagnosis of GCT-TT, as they will be used for segregation analysis of suspected variants found in the proband.

Control Cohort

  • Must be ≥ 18 years of age AND
  • Must be an English-speaker AND
  • Must not have a personal history of cancer, with the exception of non-melanoma skin cancer, AND
  • Must not have a family history of germ cell tumor or testicular tumor AND
  • Must not be a blood relative of controls enrolled in this study

Exclusion criteria

Exclusion Criteria:

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • A: suspicion of germ cell tumor and/or a testicular mass

    patients with testicular GCTs and non-GCT testicular tumors, extragonadal male GCTs, and female GCTs,

    Behavioral: Questionnaires · Other: sample of blood or saliva

  • B: family members of Group A

    relatives of patients with GCTs or testicular tumors

    Behavioral: Questionnaires · Other: sample of blood or saliva

  • C: healthy controls unrelated to Group A or B

    healthy controls who are unrelated to Groups A or B and do not have a personal history of cancer nor a family history of GCT or non-GCT testicular tumors

    Behavioral: Questionnaires · Other: sample of blood or saliva

Interventions

  • BehavioralQuestionnaires
  • Othersample of blood or saliva

    A sample of blood or saliva will be obtained for DNA extraction. Approximately 2-4 tubes of blood will be collected or one tablespoon of saliva. If a participant has already provided a DNA sample for another MSKCC IRB approved protocol, they may not need to provide an additional sample.

06

What researchers measure

Primary outcomes

  1. creation of a Germ Cell Tumor and testicular tumor registry

    We will collect clinical data including diagnosis date, pathology, family history, and risk factors in patients with GCT-TT.

    Time frame: 5 years

07

Study locations

6 of 8 sites recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2014 (actual). Primary completion is estimated for Jan 2028, 168 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2014
First posted
Mar 31, 2014
StartActual
Jan 2014
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: •••4311→•••4039. See the current contact
Nov 4, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Memorial Sloan Kettering Cancer Center · New York, United StatesContact removed •••4311
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Contact Study contact changed: •••4311→•••4039. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Memorial Sloan Kettering Cancer Center · New York, United StatesContact removed •••4311
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02099734
Responsible party
Sponsor
First posted
Mar 31, 2014
Start date
Jan 2014
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Darren Feldman, MD
Contact
646-422-4491
Zsofia Stadler, MD
Contact
646-888-4039
Darren Feldman, MD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion